VisualSonics, a fully-owned subsidiary of SonoSite (SONO), and a market leader in real time, in vivo, superior resolution micro-imaging systems, is exhibiting its new Vevo LAZR Photoacoustics Imaging system at the annual conference of the American Association of Cancer Research being held in Orlando, Florida, from April 2 to April 6, 2011
VisualSonics has designed its latest system for use in pre-clinical research and it may bring about a significant breakthrough in oncology research. The application of this technology on humans is envisioned in the near future.
According to an academic expert, the Vevo LAZR is a remarkable development with wide range of possibilities for cancer researchers. In the last few years, the battle against cancer has focused around preventing growth by using drugs (such as anti-angiogenesis therapeutics). If angiogenesis can be curbed, then growth of tumors can be controlled with notably diminished damage to their host bodies.
In addition, the capability to monitor the impact that a drug is having on tumor progression is a significant contribution of oncology therapy. The reality is that tumors can now be monitored in living host bodies (for instance rats) while obviating a biopsy.
Currently, scholars must frequently rely on ex vivo methodology, such as immunohistochemistry or histology, to gather molecular data within a tumor. The in vivo methods, reduce the number of animals needed for research, by following the same animal during disease development and therapy.
VisualSonics also maintains that its Vevo LAZR Photoacoustics system is a significant development with respect to in vivo imaging knowhow. The enhancements to this product will permit cancer specialists to speed up their research on the functioning of the cancerous cells and the tissue of the host body in which they reside.
The capability to carry out microscopic research on live bodies in a non-invasive manner, will permit VisualSonics’ clients to provide speedy and life-saving facility.
The Vevo LAZR system is a part of VisualSonics’ on-going efforts to provide researchers with new methods for improving pre-clinical research. The Vevo LAZR system has applications ranging from study of hemoglobin and oxygen saturation to lymph node imaging and targeted imaging of tumor biomarkers. Besides cancer research, this modern imaging system will be useful in other research areas such as neurosciences and diabetes.
VisualSonics enjoys global leadership in real time, in vivo, high-resolution micro imaging technology geared for preclinical research. The company’s know how enables researchers to conduct research in cancer, cardiovascular, neurobiology and other areas. Its micro imaging knowledge supports research in such areas as drug development and genetic research.
Seattle-based SonoSite is a global leader in point-of-care and bedside ultrasound. It is also a leader in the areas of ultra high-frequency micro-ultrasound know how. The company’s small and light systems are increasing the use of ultrasound for a wide range of clinical requirements by providing ultrasound at the patient point of care.
The company competes with GE Healthcare, a subsidiary of General Electric Co. (GE), and Philips Healthcare, a subsidiary of Philips (PHG), in certain niches.
GENL ELECTRIC (GE): Free Stock Analysis Report
KONINKLIJKE PHL (PHG): Free Stock Analysis Report
SONOSITE INC (SONO): Free Stock Analysis Report
Zacks Investment Research
